Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis-Reference-Cited by-同舟云学术

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

Published:2010-12-08 Issue:3 Volume:33 Page:313-322
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Kruis W.,Jonaitis L.,Pokrotnieks J.,Mikhailova T. L.,Horynski M.,Bátovský M.,Lozynsky Y. S.,Zakharash Y.,Rácz I.,Kull K.,Vcev A.,Faszczyk M.,Dilger K.,Greinwald R.,Mueller R.,

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2010.04537.x/fullpdf

Reference21 articles.

1. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis;Sutherland;Cochrane Database Syst Rev,2006

2. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group;Fockens;Eur J Gastroenterol Hepatol,1995

3. An oral preparation of mesalazine as long-term maintenance therapy for ulcerative colitis. A randomized placebo-controlled trial;Hanauer;Ann Intern Med,1996

4. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study;Paoluzi;Aliment Pharmacol Ther,2005

5. Systematic review: the use of mesalazine in inflammatory bowel disease;Bergman;Aliment Pharmacol Ther,2006

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05

2. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009;Zeitschrift für Gastroenterologie;2023-08

3. Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms;Meditsinskiy sovet = Medical Council;2022-08-10

4. Is it time to include older adults in inflammatory bowel disease trials? A call for action;The Lancet Healthy Longevity;2022-05

5. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase;PLOS ONE;2021-08-04